研究業績 2025年

  • Toyoda Y, Pavelcova K, Masinova J, Hasikova L, Zavada J, Hanova P, Klein M, Vavra J, Takada T, Stiburkova B. Identification of pathogenic variants in the ABCG2 gene in patients with severe familial hyperuricemia and gout. Mol Cell Biochem 2025 in press. [abstract]
  • Taguchi S, Kawai T, Kurokawa Y, Saegusa N, Yamamoto M, Ambe Y, Honda K, Maki K, Fujii Y, Miyakawa J, Tokura Y, Inoue H, Kaneko T, Tanaka T, Nara K, Kamei J, Kakutani S, Yamada Y, Niimi A, Yamada D, Takada T, Nakagawa T, Kume H. The first real-world evidence on dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin followed by switch maintenance avelumab in advanced urothelial carcinoma: a propensity score-matched study. Int J Clin Oncol 2025 in press. [open access]
  • Ito SM, Yamanashi Y, Suzuki H, Takada T. Preclinical evaluation of new drug-drug interactions of lomitapide: A proposal for novel mechanism of interaction associated with lipid metabolic changes. Biochem Pharmacol 2025 233:116778. [open access]
  • Miyata Y, Yamaguchi R, Yamamoto T, Kishida T, Ikeuchi K, Harada H, Tsutsumi T, Fujio K, Takada T. Drug-drug interaction between ensitrelvir and tacrolimus in a patient undergoing treatment for COVID-19: a case report. J Pharm Health Care Sci 2025 11(1):3. [open access]
  • Morita K, Sato K, Tomabechi R, Yamaya R, Takada T, Kishimoto H, Higuchi K, Inoue K. Luciferase-based bioluminescence revealed the facilitated diffusion of D-luciferin mediated by SLC17A3. Biochem Biophys Res Commun 2025 749:151360. [abstract]
  • Kawai T, Kurokawa Y, Taguchi S, Honda K, Maki K, Ambe Y, Saegusa N, Yamamoto M, Miyakawa J, Tokura Y, Inoue H, Tanaka T, Nara K, Kaneko T, Fujii Y, Kamei J, Kakutani S, Yamada Y, Niimi A, Yamada D, Takada T, Nakagawa T, Kume H. Optimization of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin therapy for Japanese patients with urothelial carcinoma. Jpn J Clin Oncol in press. [abstract]
  • Matake I, Yasujima T, Matsuo H, Toyoda Y, Kawamura Y, Takada T, Inoue K, Yamashiro T, Yuasa H. Functional characteristics of equilibrative nucleoside transporter 2 (ENT2/SLC29A2) for the transport of urate as a newly identified substrate. Drug Metab Pharmacokinet in press. [open access]